JP2022537515A5 - - Google Patents
Info
- Publication number
- JP2022537515A5 JP2022537515A5 JP2021573591A JP2021573591A JP2022537515A5 JP 2022537515 A5 JP2022537515 A5 JP 2022537515A5 JP 2021573591 A JP2021573591 A JP 2021573591A JP 2021573591 A JP2021573591 A JP 2021573591A JP 2022537515 A5 JP2022537515 A5 JP 2022537515A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- protein according
- cancer
- antigen
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019090494 | 2019-06-10 | ||
| CNPCT/CN2019/090494 | 2019-06-10 | ||
| PCT/CN2020/095354 WO2020249003A1 (en) | 2019-06-10 | 2020-06-10 | Antibody-interleukin fusion protein and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022537515A JP2022537515A (ja) | 2022-08-26 |
| JP2022537515A5 true JP2022537515A5 (enExample) | 2023-06-19 |
Family
ID=73781610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573591A Pending JP2022537515A (ja) | 2019-06-10 | 2020-06-10 | 抗体－インターロイキン融合タンパク質および使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220306713A1 (enExample) |
| EP (1) | EP3980067A4 (enExample) |
| JP (1) | JP2022537515A (enExample) |
| CN (1) | CN114599390A (enExample) |
| CA (1) | CA3143218A1 (enExample) |
| WO (1) | WO2020249003A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021231741A2 (en) * | 2020-05-14 | 2021-11-18 | Elixiron Immunotherapeutics (hong Kong) Limited | Anti-pd-l1 antibodies and anti-pd-l1/il10 fusion proteins |
| IL305758A (en) * | 2021-03-10 | 2023-11-01 | Immunowake Inc | Immunomodulatory compounds and their uses |
| CN115838424A (zh) * | 2021-09-22 | 2023-03-24 | 上海康岱生物医药技术股份有限公司 | 靶向tigit的单克隆抗体 |
| KR20240074772A (ko) * | 2021-10-10 | 2024-05-28 | 엘릭시론 이뮤노테라퓨틱스 (홍콩) 리미티드 | 항-pd-l1/il-10 융합 단백질을 이용한 질병 치료 방법 |
| WO2023078245A1 (zh) * | 2021-11-02 | 2023-05-11 | 广东菲鹏制药股份有限公司 | Il10单体融合蛋白及其应用 |
| CN116063547A (zh) * | 2022-07-08 | 2023-05-05 | 盛禾(中国)生物制药有限公司 | 一种二聚体融合蛋白及其应用 |
| CN118221829A (zh) * | 2022-12-21 | 2024-06-21 | 广东菲鹏制药股份有限公司 | 一种il-10单体融合蛋白 |
| AU2024360651A1 (en) * | 2023-10-08 | 2026-04-23 | Guangdong Fapon Biopharma Inc. | Anti-pd1-il10 fusion protein and use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2344540T3 (enExample) * | 2008-10-02 | 2018-04-28 | ||
| CN120242030A (zh) * | 2013-11-11 | 2025-07-04 | 阿尔莫生物科技股份有限公司 | 将白细胞介素-10用于治疗疾病和病症的方法 |
| WO2015117930A1 (en) * | 2014-02-06 | 2015-08-13 | F. Hoffmann-La Roche Ag | Interleukine 10 immunoconjugates |
| BR112017001385B1 (pt) * | 2014-07-22 | 2023-12-05 | Cb Therapeutics, Inc. | Anticorpo isolado ou fragmento do mesmo que liga a pd-1, uso deste, composição, polinucleotídeo isolado e vetor de expressão |
| KR102476226B1 (ko) * | 2014-08-05 | 2022-12-12 | 아폴로믹스 인코포레이티드 | 항-pd-l1 항체 |
| CN116769054A (zh) * | 2016-02-05 | 2023-09-19 | 奥里尼斯生物科学私人有限公司 | 双特异性信号传导剂及其用途 |
| US20200353050A1 (en) * | 2017-11-10 | 2020-11-12 | Armo Biosciences, Inc. | Compositions and methods of use of interleukin-10 in combination with immune check-point pathway inhibitors |
-
2020
- 2020-06-10 CN CN202080055588.4A patent/CN114599390A/zh active Pending
- 2020-06-10 EP EP20822767.8A patent/EP3980067A4/en not_active Withdrawn
- 2020-06-10 US US17/617,945 patent/US20220306713A1/en not_active Abandoned
- 2020-06-10 CA CA3143218A patent/CA3143218A1/en active Pending
- 2020-06-10 JP JP2021573591A patent/JP2022537515A/ja active Pending
- 2020-06-10 WO PCT/CN2020/095354 patent/WO2020249003A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022537515A5 (enExample) | ||
| Tapia-Galisteo et al. | Bi-and trispecific immune cell engagers for immunotherapy of hematological malignancies | |
| JP2020103301A5 (enExample) | ||
| JP2022159548A5 (enExample) | ||
| JP2022177097A (ja) | ヘテロ二量体多重特異性抗体フォーマット | |
| RU2017145150A (ru) | Антитело против pdl-1, его фармацевтическая композиция и применение | |
| Feldmann et al. | Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T cells | |
| JP2022515318A5 (enExample) | ||
| RU2017115315A (ru) | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения | |
| JP2019532619A5 (enExample) | ||
| JP2021502810A5 (enExample) | ||
| RU2022102446A (ru) | Биспецифические связывающие белки и пути их применения | |
| JP2020534830A5 (enExample) | ||
| JP2019531697A5 (enExample) | ||
| JP2021516051A5 (enExample) | ||
| ES3036457T3 (en) | A cd33-, cd16- and cd123-specific single chain triplebody | |
| JP2023540526A5 (enExample) | ||
| JP2021530244A5 (enExample) | ||
| JP2022512891A5 (enExample) | ||
| CN115461373A (zh) | 密蛋白18.2的抗体及其用途 | |
| JP2021529776A5 (enExample) | ||
| RU2019104896A (ru) | Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и способы их использования | |
| JP2023510429A5 (enExample) | ||
| JP2024543043A5 (enExample) | ||
| JP2019524111A5 (enExample) |